BiomX (PHGE) Other Non-Current Liabilities (2018 - 2026)
BiomX's (PHGE) quarterly Other Non-Current Liabilities came in at $2.4 million in Q2 2026, down 44.9% year-over-year from $4.4 million in Q2 2025, and up 44.04% quarter-over-quarter from $1.7 million in Q1 2026.
Analysis
BiomX (PHGE) Other Non-Current Liabilities (2018 - 2026) Analysis & Trends
BiomX has disclosed Other Non-Current Liabilities across 9 years of filings, most recently posting $2.4 million for Q2 2026.
- In Q2 2026, Other Non-Current Liabilities fell 44.9% year-over-year to $2.4 million; the TTM figure through Jun 2026 stood at $2.4 million (down 44.9% YoY), while the FY2025 annual figure was $706000.0, down 69.13% from the prior year.
- Other Non-Current Liabilities came in at $2.4 million for Q2 2026 at BiomX, up from $1.7 million in the prior quarter.
- In the past five years, Other Non-Current Liabilities ranged from a high of $24.9 million in Q2 2024 to a low of $148000.0 in Q3 2023.
- Average Other Non-Current Liabilities over 5 years is $3.1 million, with a median of $706000.0 recorded in 2025.
- Year-over-year, Other Non-Current Liabilities surged 12998.42% in 2024 and tumbled 82.3% in 2025.
- Over 5 years, Other Non-Current Liabilities stood at $188000.0 in 2022, then slipped by 17.55% to $155000.0 in 2023, then soared by 1375.48% to $2.3 million in 2024, then slumped by 69.13% to $706000.0 in 2025, then soared by 243.77% to $2.4 million in 2026.
- Per Business Quant data, the three most recent Other Non-Current Liabilities figures were $2.4 million in Q2 2026, $1.7 million in Q1 2026, and $706000.0 in Q4 2025.
Peer Set
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Amgen | 211.28 Bn | 197.29 Bn | 7.24 Bn |
| 2 | Gilead Sciences | 180.97 Bn | 177.80 Bn | 6.22 Bn |
| 3 | Vertex Pharmaceuticals | 132.56 Bn | 124.70 Bn | 2.84 Bn |
| 4 | Regeneron Pharmaceuticals | 82.34 Bn | 74.34 Bn | 3.93 Bn |
| 5 | Argenx Se | 60.73 Bn | 55.54 Bn | 1.37 Bn |
| 6 | Moderna | 52.08 Bn | 46.95 Bn | 52.00 Mn |
| 7 | Alnylam Pharmaceuticals | 33.90 Bn | 30.59 Bn | 992.69 Mn |
| 8 | Biogen | 31.21 Bn | 29.93 Bn | 1.96 Bn |
| 9 | Roivant Sciences | 29.68 Bn | 29.68 Bn | 1.16 Mn |
| 10 | BiomX | 17.27 Mn | 16.70 Mn | 97,000.00 |
Historic Data
Download Data
Historic Data
| Date | Value |
|---|---|
| Jun 30, 2026 | 2.43 Mn |
| Mar 31, 2026 | 1.69 Mn |
| Dec 31, 2025 | 706,000.00 |
| Sep 30, 2025 | 5.14 Mn |
| Jun 30, 2025 | 4.41 Mn |
| Mar 31, 2025 | 5.90 Mn |
| Dec 31, 2024 | 2.29 Mn |
| Sep 30, 2024 | 4.33 Mn |
| Jun 30, 2024 | 24.89 Mn |
| Dec 31, 2023 | 155,000.00 |
| Sep 30, 2023 | 148,000.00 |
| Jun 30, 2023 | 190,000.00 |
| Mar 31, 2023 | 192,000.00 |
| Dec 31, 2022 | 188,000.00 |
| Sep 30, 2022 | 206,000.00 |
| Jun 30, 2022 | 209,000.00 |
| Mar 31, 2022 | 215,000.00 |
| Dec 31, 2021 | 215,000.00 |
| Sep 30, 2021 | 420,000.00 |
| Jun 30, 2021 | 419,000.00 |